Improved availability of new cancer therapies ‘set to continue’

Cancer outcomes worldwide are likely to continue to improve due to the robust pipeline of new oncology drugs currently in development.

This is according to a new report from the QuintilesIMS Institute, which indicated that 68 novel therapies have been approved across 22 cancer indications globally since 2011, resulting in more treatment options, greater access and improved outcomes, especially for those with metastatic disease.

Additionally, 631 unique molecules are now in late-stage development, marking a 7.7 percent increase from a year ago, with personalised therapies based on predictive biomarkers becoming particularly common.

In the past five years, clinical development has become more efficient, with investigational timelines becoming shorter, regulatory review periods being minimised and efforts made to ensure superseding treatments are made available promptly.

Murray Aitken, senior vice-president and executive director of the QuintilesIMS Institute, said: "The launch of multiple novel agents, coupled with increasing awareness and focus on cancer prevention, and emphasis on early diagnosis, have contributed to improved outcomes and a reduction in mortality rates for many of the major cancers over the past decade."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.